United States Patent 9,545,399: What Is Claimed in Scope, and Where Does It Sit in the Methylphenidate ER Landscape?
US 9,545,399 is directed to an extended-release (ER) racemic methylphenidate chewable tablet built around a sustained-release (SR) racemic methylphenidate-cation exchange resin complex that is overcoated with a water-insoluble, water-permeable, pH-independent barrier coating in a defined weight range. The tablet also includes at least one immediate-release (IR) racemic methylphenidate component that provides early exposure within an in vitro dissolution window (less than ~30 minutes; some dependent claims narrow to ~10 minutes). The claims tie composition and coating build to specific pharmacokinetic exposure bands (AUC and Cmax) after a single oral chewable dose equivalent to 40 mg racemic methylphenidate HCl in adults under fasted and fed conditions. The claims also require chewability functionality: tablets are dividable into portions that retain an ER profile.
What matters for freedom-to-operate (FTO): the core novelty in the claim set is not merely “ER methylphenidate” or “chewable methylphenidate.” It is the combination of (1) resin complex + pH-independent barrier coating (with quantified barrier loading and defined coating chemistries), (2) IR/SR ratio windows for the methylphenidate delivered over time, and (3) PK target bands tied to the chewable tablet, including single-peak behavior and time-window equivalence to a referenced curve.
1) What Is the Independent Claim 1 Really Requiring?
Claim 1 architecture (functional + structural)
Claim 1 requires all of the following in one product:
-
Dosage form
- “An extended release racemic methylphenidate chewable tablet” that is a uniform solid dispersion.
-
Sustained-release component: resin complex + barrier
- A “sustained release racemic methylphenidate component” comprising:
- a water-insoluble, water-permeable, pH-independent barrier coated racemic methylphenidate-cation exchange resin complex,
- the resin complex may be in an optional polymeric matrix,
- the barrier coating is over the resin complex (and optional matrix).
- Barrier coating loading
- barrier coating present at about 20% w/w to about 50% w/w (as stated relative to the resin complex–optional matrix base).
- Polymeric matrix options
- polymeric matrix (when present) can comprise:
- the resin complex plus a water-insoluble polymer or copolymer, or
- a water-soluble polymer or copolymer.
-
Immediate-release component (IR) + early in vitro release
- “At least one immediate release racemic methylphenidate component” that provides release:
- “in less than about 30 minutes” in an in vitro dissolution assay.
-
IR/SR exposure mix by weight
- Based on total racemic methylphenidate active in the tablet:
- about 50% w/w to about 90% w/w is provided by the sustained-release component.
-
Divisibility and ER retention
- Tablet is capable of being divided and each tablet portion retains a therapeutically effective extended release profile and PK profile attributes described in the claim.
-
PK bands in adults after single chewable dose
- Dose: “equivalent of 40 mg racemic methylphenidate HCl.”
- Under fasted and fed conditions following a single oral administration:
- geometric mean AUC0-∞ about 110 to 140 ng·hr/mL, or
- geometric mean Cmax about 10 to 15 ng/mL.
- Additional PK constraints are reinforced throughout dependent claims:
- single-peak behavior (claim 22),
- equivalence to a reference curve (claim 24),
- and confidence interval requirements for test/reference ratios for AUC windows (claim 23).
2) How Does the Dependent Claims Narrow Formulation and Performance?
Core dependent claim constraints
Below are the principal narrowing hooks that matter for design-around.
| Claim |
Limitation that narrows scope |
| 2 |
IR component releases in about 10 minutes (stricter than claim 1’s <30 minutes). |
| 3 |
Sustained-release component provides about 60% to 80% of tablet methylphenidate (tightens the 50% to 90% window). |
| 4 |
IR component can be a methylphenidate-cation exchange resin complex (important because it keeps the resin theme also for IR). |
| 5 |
When claim 4 is used, IR resin complex comprises about 20% to 40% of total methylphenidate. |
| 6 |
IR component can be uncomplexed methylphenidate or a salt. |
| 7 |
Salt example: racemic methylphenidate HCl. |
| 8 |
If uncomplexed: IR uncomplexed racemic methylphenidate HCl is about 5% to 35% of total methylphenidate. |
| 9 |
Tablet hardness: 8 kp to 23 kp. |
| 10 |
Barrier coating selection and tensile strength range: 150% to 400% tensile strength; options include PVAc-based, acrylic-based, or solvent ethylcellulose coating. |
| 11 |
PVAc barrier coating composition: 70% to 90% PVAc, 2% to 10% stabilizer/plasticizer ranges (as stated). |
| 12 |
Barrier coating layer is about 25% to 35% by weight of the coated resin complex–optional matrix. |
| 13 |
Polymer matrix option: polyvinylpyrrolidone. |
| 14 |
Polymer matrix option: includes a water-insoluble polymer. |
| 15 |
Acrylic barrier blend with specific chemistries and ratios for one polymer/copolymer blend. |
| 16 |
Tablet has non-functional outer top coating layer. |
| 18 |
Tablet is scored (divisibility). |
| 19 |
Method claim: orally administer a single chewable tablet of claim 1 to treat ADHD/ADD. |
| 20 |
In vitro dissolution cap: no more than ~55% of methylphenidate released within one hour. |
| 21 |
More than one IR methylphenidate component permitted. |
| 22 |
PK: “single mean plasma concentration peak.” |
| 23 |
PK: requires that 90% confidence intervals of geometric test/reference ratios of AUC0-3 or AUC0-4 (refers to FIG. 1). |
| 24 |
PK curve equivalence: plasma concentration curve from 0 to 8 hours matches FIG. 1 under fasted/fed at 40 mg equivalent. |
| 25-27 |
Tablet strength examples: equivalent of 40 mg, 20 mg, 30 mg. |
Where claim narrowing is strongest
The most “design-sensitive” elements are:
-
Barrier coating chemistry + mechanical property + loading
- “pH-independent,” “water-insoluble, water-permeable,” plus tensile strength 150% to 400%.
- Barrier composition options include PVAc, acrylic ethyl acrylate/methyl methacrylate systems, and ethylcellulose with plasticizer.
- Barrier loading windows: 20% to 50% w/w (claim 1) and 25% to 35% (claim 12) in specific embodiments.
-
IR window and IR fraction
- IR release: <30 minutes; dependent claims push to ~10 minutes.
- IR fraction: 5% to 35% when using uncomplexed; 20% to 40% when using resin complex as IR.
-
IR/SR ratio that drives dissolution and PK
- Sustained-release methylphenidate is 50% to 90% overall; dependent 60% to 80%.
- Dissolution performance: no more than ~55% released within one hour.
-
PK acceptance band
- AUC0-∞ 110 to 140 or Cmax 10 to 15 ng/mL under fasted/fed.
- Single-peak mean profile plus curve equivalence to FIG. 1 through 8 hours.
These constraints mean a product that differs on the barrier concept or resin complex build has the strongest chance of avoiding literal claim 1, but the claim set also has multiple dependent fallbacks, including multiple barrier coating chemistries and matrix variations.
3) What Compositional and Manufacturing Features Are Captured by Claim Language?
Barrier coating function
The independent claim is explicit about a barrier that is simultaneously:
- water-insoluble
- water-permeable
- pH-independent
and that barrier coats the racemic methylphenidate-cation exchange resin complex (optionally in a polymeric matrix), with defined weight placement and loading.
Materials covered
Dependent claims enumerate specific barrier coating material classes:
- PVAc-based aqueous dispersion (with stabilizer and plasticizer) under a defined formulation range.
- Acrylic-based pH-independent coating using ethyl acrylate and methyl methacrylate based polymer/copolymer chemistries, including specific quaternized monomer versions with stated ratios.
- Solvent-based ethylcellulose coating, optionally with plasticizer.
Mechanical property
The barrier coating is captured with a tensile strength range:
Matrix involvement
Claim 1 frames the polymeric matrix as optional, but dependent claims pull matrix into the story:
- PVPP (polyvinylpyrrolidone) as polymer matrix.
- Or water-insoluble polymer matrix.
This matters because the barrier is “over” the resin complex “-optional matrix,” so if a competitor omits the matrix or uses a materially different matrix strategy, the barrier-over-resin complex arrangement may still map, but some specific embodiments narrow further.
Tablet integrity and chewability
The tablet must be:
- dividable (claim 1),
- can retain ER profile after division,
- is scored in one embodiment (claim 18),
- has hardness 8 kp to 23 kp (claim 9).
4) What the Scope Means for Patent Landscape and Competitor Strategies
This patent is positioned as a “product-by-structure and performance” claim
The claim language blends:
- structural/formulation features (resin complex, barrier coating with defined properties and composition options),
- unit-dose manufacturing characteristics (chewable tablet, uniform solid dispersion),
- and performance targets (dissolution time window, one-hour release cap, and fasted/fed PK bands with specific geometric mean thresholds and curve equivalence).
That combination is a pattern seen in second-generation ER stewardship: the claims are drafted to lock in both the physical engineering (barrier coating and loading) and the PK outcome band for a particular dose (40 mg equivalent).
Likely infringement theory boundaries
For a generic or reformulation competitor, exposure risk rises if the product:
- uses a resin complex for sustained release,
- uses a pH-independent water-insoluble/water-permeable barrier coating over that resin complex,
- matches barrier loading ranges (20% to 50% w/w in claim 1; 25% to 35% in claim 12),
- hits IR release timing (<30 minutes; possibly ~10 minutes),
- keeps sustained-release fraction in the 50% to 90% band,
- and reproduces PK bands (AUC0-∞ 110 to 140 or Cmax 10 to 15 ng/mL) under fasted/fed.
Most direct design-around levers (conceptually)
Without asserting feasibility, the claim set’s tightest “gate” is the barrier coating definition:
- switching away from a pH-independent water-insoluble/water-permeable barrier (or altering barrier loading so it falls outside the defined w/w ranges),
- or changing the sustained-release mechanism away from the resin complex + barrier architecture,
can break claim 1 mapping.
A second gate is the PK target band:
- If a product’s geometric mean AUC0-∞ or Cmax falls outside the stated windows under fasted/fed, it may avoid the literal language that ties the product to those PK outcomes.
A third gate is divisibility:
- claim 1 requires dividable tablet portions that retain ER and PK profiles.
- claim 18 adds scored tablet as a dependent embodiment.
Method claim coverage
Claim 19 is a direct use claim:
- treat ADHD/ADD by oral administration of a single claim 1 tablet.
This is relevant for label and prescribing scope when a product is approved for ADHD/ADD indications.
5) How to Read This as a “Core” Patent vs. an “Anchor” Claim in Litigation
From the claim drafting:
- Claim 1 is the anchor because it combines formulation and PK.
- Claims 10 to 15 are “material fallback” routes that keep coverage broad even if a product uses PVAc versus acrylic barrier versus ethylcellulose barrier.
- Claims 2, 3, 8, 20, 22, 23, 24 create performance-based fences.
- Claims 25 to 27 show multiple strengths are in view (20 mg, 30 mg, 40 mg equivalents), which is relevant for product families.
In a landscape context, this set functions like an engineering “fingerprint” rather than a narrow chemical compound patent.
Key Takeaways
- US 9,545,399 covers an ER racemic methylphenidate chewable that uses a sustained-release methylphenidate-cation exchange resin complex coated with a water-insoluble, water-permeable, pH-independent barrier, with defined barrier loading and specified coating material options.
- The tablet also includes immediate-release racemic methylphenidate with dissolution release timing and defined IR fraction windows, including both resin-complex IR and uncomplexed IR salt embodiments.
- The claim set is anchored to fasted and fed adult PK targets after a single 40 mg equivalent dose, using explicit geometric mean AUC0-∞ (110 to 140 ng·hr/mL) and/or Cmax (10 to 15 ng/mL) requirements, plus single-peak behavior and curve equivalence to a referenced figure.
- Dependent claims tighten scope via barrier composition and tensile strength, dissolution caps (<=55% in 1 hour), hardness, and divisibility (scored embodiments).
- The tightest infringement risk sits where competitors match the barrier concept and loading and also reproduce PK bands for the chewable product.
FAQs
1) What is the main novelty in claim 1?
A sustained-release architecture in which a racemic methylphenidate-cation exchange resin complex is coated with a pH-independent, water-insoluble but water-permeable barrier at defined weight loading, combined with an IR component and tied to specific fasted/fed PK bands for a 40 mg equivalent dose.
2) Does the patent require resin complex for both SR and IR?
No. Claim 1 requires SR to be resin-complex based. IR can be either a resin complex (claim 4/5) or uncomplexed methylphenidate or salt (claim 6-8).
3) How fast must the immediate-release component dissolve?
Claim 1 requires less than about 30 minutes in an in vitro dissolution assay; claim 2 narrows to about 10 minutes.
4) What PK outcomes are specified?
Geometric mean AUC0-∞ about 110 to 140 ng·hr/mL and/or geometric mean Cmax about 10 to 15 ng/mL after a single oral dose equivalent to 40 mg racemic methylphenidate HCl under fasted and fed conditions.
5) Are multiple strengths covered?
Yes. Dependent claims reference tablet dose equivalents of 40 mg, 30 mg, and 20 mg racemic methylphenidate HCl.
References
- U.S. Patent No. 9,545,399.
